Biosig Technologies (BSGM) Projected to Post Earnings on Wednesday

Posted by Editorial Team on Aug 12th, 2025

Biosig Technologies (NASDAQ:BSGM – Get Free Report) is expected to release its earnings data before the market opens on Wednesday, August 13th. Analysts expect Biosig Technologies to post earnings of ($0.04) per share for the quarter.

Biosig Technologies (NASDAQ:BSGM – Get Free Report) last issued its earnings results on Monday, May 19th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.09). On average, analysts expect Biosig Technologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biosig Technologies Stock Up 9.1%

Shares of Biosig Technologies stock opened at $4.09 on Tuesday. The company has a fifty day moving average of $6.24 and a 200 day moving average of $3.09. Biosig Technologies has a fifty-two week low of $0.23 and a fifty-two week high of $14.11.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Biosig Technologies stock. Geode Capital Management LLC lifted its position in Biosig Technologies, Inc. (NASDAQ:BSGM – Free Report) by 73.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 221,164 shares of the company’s stock after purchasing an additional 93,493 shares during the quarter. Geode Capital Management LLC owned about 0.71% of Biosig Technologies worth $1,580,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 7.16% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets upped their target price on shares of Biosig Technologies from $2.50 to $10.00 and gave the stock a “buy” rating in a report on Friday, June 6th.

Get Our Latest Stock Analysis on Biosig Technologies

About Biosig Technologies

(Get Free Report)

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.